Drug intelligence / Profile preview

ENDO-210

Development stage: Preclinical
Lead developer: EndoCyclic Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

ENDO-210 is a targeted diagnostic agent developed for the definitive MRI diagnosis of endometriosis. It enables the detection of sub-millimeter endometriosis lesions that are otherwise undetectable by conventional imaging methods. ENDO-210 can be used as a standalone diagnostic or as a companion diagnostic to ensure accurate disease identification and elimination, supporting both diagnosis and monitoring of treatment efficacy in endometriosis patients. The agent is part of EndoCyclic Therapeutics' proprietary platform focused on gynecological and cancer disorders[1][2].

Beyond the preview

Go deeper on ENDO-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENDO-210.

Explore the full profile